Posted by Michael Wonder on 18 Mar 2026
EMA grants PRIME designation to TolerogenixX’s MIC-Lx therapy for donor-specific immune tolerance in kidney transplantation
11 March 2026 - TolerogenixX today announced that the EMA has granted PRIority MEdicines (PRIME) designation to its lead cell therapy candidate MIC-Lx for individualised immuno-suppression in living donor kidney transplantation.
The PRIME designation follows a positive assessment by the Committee for Advanced Therapies and endorsement by the CHMP during its February 2026 meeting.
